In a roundup review of scientific studies recently published, a study out of RCSI University of Medicine and Health Sciences and the HSE Health Protection Surveillance Centre (HPSC) in Ireland further defined the association between comorbidities and poor outcomes with Covid-19.

A small trial of Eli Lilly’s donanemab showed the experimental Alzheimer’s drug slowed by about a third the rate of decline in a combined measure of cognition and function in patients at an early stage of the mind-wasting disease.

Biogen announced the widely awaited submission of a U.S. marketing application for the experimental Alzheimer’s therapy aducanumab, sending the company’s shares up more than 8 percent before the bell.

Biogen Inc. and partner Eisai Co. Ltd. are ending two late-stage trials for the experimental Alzheimer’s drug aducanumab, in a setback to efforts to find treatments for the disease and for Biogen’s stock, which lost more than $17 billion of the company’s value.

Scientists at DZNE, HIH, and the University Hospital Tuebingen identified a protein in blood that can precisely track Alzheimer’s disease progression before the first symptoms appear.

Here is a look at BioSpace’s top 10 stories of 2018.

U.S. drugmaker Eli Lilly and Co. and AC Immune SA agreed to jointly develop the Swiss biotech’s potential treatment for Alzheimer’s disease.

Eli Lilly scrapped a Phase II clinical trial for N3pG, a humanized IgG1 monoclonal antibody, plus BACE in the treatment of Alzheimer’s.

Researchers at the University of Texas Health Science Center at San Antonio found a type of cellular stress in Alzheimer’s disease for the first time that is involved in cancer and aging.

The U.S. FDA declined to approve Pain Therapeutics Inc.’s abuse-deterrent opioid treatment Remoxy for the fourth time.